InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Theravance Biopharma, Inc.

TBPH Clue Score61
United States Fiscal year ends December CIK 0001583107
$17.03 +0.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $17.03 +100.59% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue48.6Operating income−180.5Net income−190.7Fiscal year 2017Revenue15.4 −68.4%Operating income−260.1Net income−285.4Fiscal year 2018Revenue60.4 +292.4%Operating income−238.8Net income−215.5Fiscal year 2019Revenue73.4 +21.6%Operating income−251.9Net income−236.5EPS, diluted−4.25Fiscal year 2020Revenue71.9 −2.1%Operating income−297.6Net income−278.0EPS, diluted−4.46Fiscal year 2021Revenue55.3 −23.0%Operating income−257.8Net income−199.4EPS, diluted−2.87Fiscal year 2022Revenue51.3 −7.2%Operating income−92.0Net income872.1EPS, diluted11.85Fiscal year 2023Revenue57.4 +11.8%Operating income−56.0Net income−55.2 −106.3%EPS, diluted−1.00 −108.4%Fiscal year 2024Revenue64.4 +12.1%Operating income−46.9Net income−56.4EPS, diluted−1.15Fiscal year 2025Revenue107.5 +66.9%Operating income−3.6Net income105.9EPS, diluted2.06
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 48.6 15.4 60.4 73.4 71.9 55.3 51.3 57.4 64.4 107.5
Growth −68.4% +292.4% +21.6% −2.1% −23.0% −7.2% +11.8% +12.1% +66.9%
Operating income −180.5 −260.1 −238.8 −251.9 −297.6 −257.8 −92.0 −56.0 −46.9 −3.6
Net income −190.7 −285.4 −215.5 −236.5 −278.0 −199.4 872.1 −55.2 −56.4 105.9
Growth −106.3%
EPS, diluted n/a n/a n/a −4.25 −4.46 −2.87 11.85 −1.00 −1.15 2.06
Growth −108.4%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Operating margin−371.0%Net margin−391.9%Free cash flow margin−207.9%Fiscal year 2017Operating margin−1,690.6%Net margin−1,855.0%Free cash flow margin−1,322.4%Fiscal year 2018Operating margin−395.5%Net margin−357.0%Free cash flow margin−199.0%Fiscal year 2019Operating margin−343.1%Net margin−322.1%Free cash flow margin−328.8%Fiscal year 2020Operating margin−414.2%Net margin−386.9%Free cash flow margin−357.7%Fiscal year 2021Operating margin−466.1%Net margin−360.6%Free cash flow margin−382.0%Fiscal year 2022Operating margin−179.1%Net margin1,698.5%Free cash flow margin−365.3%Fiscal year 2023Operating margin−97.6%Net margin−96.1%Free cash flow margin−51.3%Fiscal year 2024Operating margin−72.9%Net margin−87.6%Free cash flow margin−18.4%Fiscal year 2025Operating margin−3.4%Net margin98.5%Free cash flow margin221.9%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −371.0% −1,690.6% −395.5% −343.1% −414.2% −466.1% −179.1% −97.6% −72.9% −3.4%
Net margin −391.9% −1,855.0% −357.0% −322.1% −386.9% −360.6% 1,698.5% −96.1% −87.6% 98.5%
Free cash flow margin −207.9% −1,322.4% −199.0% −328.8% −357.7% −382.0% −365.3% −51.3% −18.4% 221.9%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−99.0Capital expenditure−2.1Free cash flow−101.1Fiscal year 2017Operating cash flow−201.1Capital expenditure−2.4Free cash flow−203.5Fiscal year 2018Operating cash flow−112.9Capital expenditure−7.2Free cash flow−120.1Fiscal year 2019Operating cash flow−238.2Capital expenditure−3.2Free cash flow−241.4Fiscal year 2020Operating cash flow−250.4Capital expenditure−6.6Free cash flow−257.0Fiscal year 2021Operating cash flow−207.9Capital expenditure−3.4Free cash flow−211.3Fiscal year 2022Operating cash flow−187.0Capital expenditure−0.6Free cash flow−187.6Buybacks−128.8Fiscal year 2023Operating cash flow−27.0Capital expenditure−2.5Free cash flow−29.5Buybacks−197.1Fiscal year 2024Operating cash flow−11.5Capital expenditure−0.3Free cash flow−11.9Buybacks−0.4Fiscal year 2025Operating cash flow238.5Capital expenditure−0.0Free cash flow238.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −99.0 −201.1 −112.9 −238.2 −250.4 −207.9 −187.0 −27.0 −11.5 238.5
Capital expenditure −2.1 −2.4 −7.2 −3.2 −6.6 −3.4 −0.6 −2.5 −0.3 −0.0
Free cash flow −101.1 −203.5 −120.1 −241.4 −257.0 −211.3 −187.6 −29.5 −11.9 238.5
Growth
Buybacks n/a n/a n/a n/a n/a n/a −128.8 −197.1 −0.4 n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2016Cash344.7Shareholders’ equity350.2Fiscal year 2017Cash89.0Total debt223.7Net cash (debt)−134.8Shareholders’ equity115.2Debt to equity1.94Fiscal year 2018Cash378.0Total debt454.4Net cash (debt)−76.3Shareholders’ equity−51.6Fiscal year 2019Cash58.1Total debt455.0Net cash (debt)−397.0Shareholders’ equity−223.8Fiscal year 2020Cash81.5Total debt619.2Net cash (debt)−537.7Shareholders’ equity−303.8Fiscal year 2021Cash90.0Total debt616.3Net cash (debt)−526.4Shareholders’ equity−338.6Fiscal year 2022Cash298.2Shareholders’ equity441.8Fiscal year 2023Cash39.5Total debt0.0Net cash (debt)39.5Shareholders’ equity213.0Debt to equity0.00Fiscal year 2024Cash37.8Shareholders’ equity175.5Fiscal year 2025Cash167.8Shareholders’ equity296.7
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 344.7 89.0 378.0 58.1 81.5 90.0 298.2 39.5 37.8 167.8
Total debt n/a 223.7 454.4 455.0 619.2 616.3 n/a 0.0 n/a n/a
Net cash (debt) n/a −134.8 −76.3 −397.0 −537.7 −526.4 n/a 39.5 n/a n/a
Shareholders’ equity 350.2 115.2 −51.6 −223.8 −303.8 −338.6 441.8 213.0 175.5 296.7
Debt to equity n/a 1.94 n/a n/a n/a n/a n/a 0.00 n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
48.6 15.4 60.4 73.4 71.9 55.3 51.3 57.4 64.4 107.5
Growth −68.4% +292.4% +21.6% −2.1% −23.0% −7.2% +11.8% +12.1% +66.9%
141.7 173.9 201.3 219.2 261.0 193.7 63.4 40.6 37.6 37.4
84.5 95.6 97.1 106.1 108.5 99.3 67.1 70.1 69.2 73.7
−180.5 −260.1 −238.8 −251.9 −297.6 −257.8 −92.0 −56.0 −46.9 −3.6
Growth
−180.6 −271.7 −226.1 −241.7 −303.3 −265.2 −92.8 −49.3 −44.6 129.2
10.1 13.7 −10.6 −5.2 −8.5 −0.2 0.0 5.9 11.8 23.4
−190.7 −285.4 −215.5 −236.5 −278.0 −199.4 872.1 −55.2 −56.4 105.9
Growth −106.3%
Per share
n/a n/a n/a −4.25 −4.46 −2.87 11.85 −1.00 −1.15 2.10
n/a n/a n/a −4.25 −4.46 −2.87 11.85 −1.00 −1.15 2.06
Growth −108.4%
n/a 53.7 55.1 55.6 62.3 69.5 73.6 55.3 48.8 50.3
n/a 52.4 54.0 55.6 62.3 69.5 73.6 55.3 48.8 51.5
Growth +3.1% +3.0% +12.1% +11.4% +5.9% −24.9% −11.7% +5.4%

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 8.4% a year over five years.
  • The diluted share count fell 17.4% in five years, so buybacks did some of the work per share.
  • Operating margin is up 410.8 points on five years ago, at -3.4%.
  • A net loss in 8 of 10 years on file.